Try a new search

Format these results:

Searched for:



Total Results:


The role of histone deacetylase inhibitors in the treatment of patients with cutaneous T-cell lymphoma

Hymes, Kenneth B
The term epigenetics refers to modifications in gene activity that occur without directly affecting the DNA sequence, and irregularities in cellular epigenetics have been implicated in the development of a number of malignancies. As such, there is considerable interest in the anticancer effects of agents that can modify cellular epigenetics. Histone deacetylase (HDAC) inhibitors represent a class of anticancer agents that have shown promise in the treatment of both solid and hematologic malignancies. Although there are a number of HDAC inhibitors in advanced stages of clinical development, vorinostat, and more recently, romidepsin, are currently the only HDAC inhibitors approved for use. Vorinostat was approved in the United States in 2006 for the treatment of cutaneous manifestations of T-cell lymphoma in patients with progressive, persistent, or recurrent disease on or following 2 systemic therapies. Romidepsin was approved in the United States in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received >/= 1 prior systemic therapy. This review aims to assess the clinical progress that vorinostat and other HDAC inhibitors have made in symptom relief and treatment of patients with CTCL and to provide practical advice for the management of associated toxicities
PMID: 20371442
ISSN: 2152-2669
CID: 109064

A 61-year-old-man with massive intravascular hemolysis [Case Report]

Uppal, Amit; Hymes, Kenneth; Schwartz, David R
PMID: 19892684
ISSN: 0012-3692
CID: 159073


Dummer, R; Hymes, K; Sterry, W; Steinhoff, M; Assaf, C; Kerl, H; Ahern, J; Rizvi, S; Ricker, J; Whittaker, S
ISSN: 0390-6078
CID: 101088

Vorinostat in combination with bexarotene in advanced cutaneous T-cell lymphoma: A phase I study [Meeting Abstract]

Dummer, R.; Hymes, K.; Sterry, W.; Steinhoff, M.; Assaf, C.; Kerl, H.; Ahern, J.; Rizvi, S.; Ricker, J. L.; Whittaker, S.
ISSN: 0732-183x
CID: 3159632

Denileukin diftitox for the treatment of cutaneous T-cell lymphoma

Kaminetzky, David; Hymes, Kenneth B
Cutaneous T-cell lymphoma/mycosis fungoides (CTCL/MF) is a rare lymphoproliferative disorder which can present as an indolent or as an aggressive process involving skin, lymph nodes, and blood. In stages IA, IB and IIA, it is usually managed with topical medications and phototherapy. If there is progression despite application of these treatments, or if the patient presents with a higher stage of disease, systemic chemotherapy or retinoids, rexinoids, biologic response modifiers are often necessary. Consequently, patients are often treated with a sequence of modalities and drugs. Denileukin diftitox (DD, Ontak(R)) is a targeted immunotoxin which has biological activity against malignancies expressing the IL-2 receptor. In addition to its unique mechanism of action, DD has a toxicity profile which does not overlap with most commonly used chemotherapeutic agents. CTCL/MF has been found be particularly susceptible to treatment with this agent. This review will describe the development DD, its proposed mechanism of action, the clinical trials which identified its utility in the treatment of CTCL/MF, the common toxicities encountered with this agent, and the management of these toxicities. In addition the incorporation of DD in the sequential treatment of CTCL/MF and data suggesting potential combination therapies employing this novel agent will be discussed
PMID: 19707452
ISSN: 1177-5475
CID: 101902

Phase II open-label trial of belinostat (PXD101) in patients with recurrent or refractory peripheral or cutaneous T-cell lymphoma [Meeting Abstract]

Foss, F; Pohlman, B; Jacobsen, E; Hymes, K; Advani, R; Kim, Y; Belt, R; Lerner, A; Ooi, C; Buhl-Jensen, P; Duvic, M
ISSN: 0923-7534
CID: 86955


Dummer, R; Hymes, K; Sterry, W; Steinhoff, M; Assaf, C; Kerl, H; Ahern, J; Rizvi, S; Ricker, JL; Whittaker, S
ISSN: 0390-6078
CID: 93278

CD20 positive mycosis fungoides: a case report

Sen, Filiz; Kang, Steven; Cangiarella, Joan; Kamino, Hideko; Hymes, Kenneth
CD20 positive T-cell lymphoma is extremely rare. Most reported cases are nodal peripheral T-cell lymphomas (PTCLs) or rarely lymphoma involving extranodal sites. Only two cases of CD20 positive T-cell lymphomas involving the skin have been previously reported and were classified as PT
PMID: 18261116
ISSN: 1600-0560
CID: 76768

Choices in the treatment of cutaneous T-cell lymphoma

Hymes, Kenneth B
Mycosis fungoides is responsive to treatment in the early stages; patients have a long duration of survival but are rarely cured of the disease. Therefore, patients require long-term, sequential therapies with as little toxicity as possible. In the early stages, skin-directed therapies, such as psoralen plus ultraviolet A in combination with retinoids or interferon, generally produce good, long-term responses. Once the disease progresses, systemic agents such as cytokines and retinoids are introduced. The cytokines provide a rational treatment approach for cutaneous T-cell lymphoma (CTCL) and produce good, long-lasting responses with few immunosuppressant effects. Denileukin diftitox (Ontak) has also been shown to produce good treatment effects, and its toxic effects can usually be controlled using prophylactic therapies. The synthetic retinoid bexarotene (Targretin) is taken orally and produces high response rates in CTCL, with a good long-term tolerability profile. Conventional systemic chemotherapies produce rapid responses and high response rates in CTCL, but these are generally of short duration and accompanied by myelosuppression and immunosuppression. Current treatment strategies therefore consist of the use of initial skin-directed therapies, with the addition of low-toxicity systemic biologic agents as the disease progresses; patients who do not respond to biologic agents should then receive conventional chemotherapies, starting with single agents and progressing to combination therapies
PMID: 17474355
ISSN: 0890-9091
CID: 95697

Zanolimumab, a fully human monoclonal antibody: early results of an ongoing clinical trial in patients with CD4(+) mycosis fungoides (MF) type CTCL(stage IB-IVB) who are refractory or intolerant to targretin and one other standard therapy [Meeting Abstract]

Duvic, M; Kim, Y; Korman, NJ; Boh, E; Lerner, A; Heffernan, MP; Hymes, KB; Pacheco, T; Elmets, CA; Lisby, S; Baadsgaard, O
ISSN: 0006-4971
CID: 71382